These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8439984)

  • 1. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant.
    MacLean GD; Reddish M; Koganty RR; Wong T; Gandhi S; Smolenski M; Samuel J; Nabholtz JM; Longenecker BM
    Cancer Immunol Immunother; 1993; 36(4):215-22. PubMed ID: 8439984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
    MacLean GD; Reddish MA; Koganty RR; Longenecker BM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
    Longenecker BM; Reddish M; Koganty R; MacLean GD
    Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
    Longenecker BM; Reddish M; Koganty R; MacLean GD
    Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
    Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
    MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
    J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
    Miles DW; Towlson KE; Graham R; Reddish M; Longenecker BM; Taylor-Papadimitriou J; Rubens RD
    Br J Cancer; 1996 Oct; 74(8):1292-6. PubMed ID: 8883420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn.
    O'Boyle KP; Zamore R; Adluri S; Cohen A; Kemeny N; Welt S; Lloyd KO; Oettgen HF; Old LJ; Livingston PO
    Cancer Res; 1992 Oct; 52(20):5663-7. PubMed ID: 1394190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
    Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
    J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
    Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
    Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
    Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy.
    Reddish MA; MacLean GD; Poppema S; Berg A; Longenecker BM
    Cancer Immunol Immunother; 1996 Jun; 42(5):303-9. PubMed ID: 8706053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
    Miles D; Papazisis K
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S134-8. PubMed ID: 12620150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
    Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-modified sialyl-Tn-CRM197 vaccine elicits a robust immune response.
    Song C; Zheng XJ; Guo H; Cao Y; Zhang F; Li Q; Ye XS; Zhou Y
    Glycoconj J; 2019 Oct; 36(5):399-408. PubMed ID: 31267246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2-->6) T antigens.
    O'Boyle KP; Markowitz AL; Khorshidi M; Lalezari P; Longenecker BM; Lloyd KO; Welt S; Wright KE
    Hybridoma; 1996 Dec; 15(6):401-8. PubMed ID: 8985750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen.
    Zhang S; Walberg LA; Ogata S; Itzkowitz SH; Koganty RR; Reddish M; Gandhi SS; Longenecker BM; Lloyd KO; Livingston PO
    Cancer Res; 1995 Aug; 55(15):3364-8. PubMed ID: 7614472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of the STn-KLH vaccine (Theratope).
    Ibrahim NK; Murray JL
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S139-43. PubMed ID: 12620151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
    Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
    Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.